Influence of intensive multifunctional neurorehabilitation on neuronal oxidative damage in patients with Huntington’s disease

Functional Neurology

Volumn 30, Issue 1, 2015, Pages 47-52

  Ciancarelli, Irene ^a,b   De Amicis, Daniela ^a   Di Massimo, Caterina ^a   Sandrini, Giorgio ^c   Pistarini, Caterina ^d   Carolei, Antonio ^a   Tozzi Ciancarelli, Maria Giuliana ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b Nova Salus Nursing and Rehabilitation Center   (Italy)

^c C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^d IRCCS   (Italy)

Author keywords

8 hydroxy 2 deoxyguanosine; Cu Zn superoxide dismutase; Huntington s disease; Neuron specific enolase; Neurorehabilitation; Oxidative stress

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; COPPER ZINC SUPEROXIDE DISMUTASE; NEURON SPECIFIC ENOLASE; 8-OXO-7-HYDRODEOXYGUANOSINE; DEOXYGUANOSINE; ENOLASE; SUPEROXIDE DISMUTASE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL EVALUATION; COGNITION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUNTINGTON CHOREA; MALE; MIDDLE AGED; MOTOR PERFORMANCE; MUSCLE STRENGTH; NEUROREHABILITATION; OXIDATIVE STRESS; PHYSICAL PERFORMANCE; QUANTITATIVE ANALYSIS; REHABILITATION MEDICINE; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; HUNTINGTON DISEASE; PROCEDURES;

DEOXYGUANOSINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; NEUROLOGICAL REHABILITATION; PHOSPHOPYRUVATE HYDRATASE; SUPEROXIDE DISMUTASE;

EID: 84938060539     PISSN: 03935264     EISSN: 19713274     Source Type: Journal    
DOI: 10.11138/FNeur/2015.30.1.047     Document Type: Article

References (40)

1. Al-Jarrah MD, Jamous M (2011). Effect of endurance exercise training on the expression of GFAP, S100B, and NSE in the striatum of chronic/progressive mouse model of Parkinson’s disease. NeuroRehabilitation 28:359-363.
2. Andrew SE, Goldberg YP, Kremer B, et al (1993). The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington’s disease. Nat Genet 4:398-403.
3. Arida RM, Scorza FA, Cavalheiro EA (2013). Role of physical exercise as complementary treatment for epilepsy and other brain disorders. Curr Pharm Des 19:6720-6725.
4. Armstrong MJ, Miyasaki JM (2012). Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 79:597-603.
5. Aziz NA, Jurgens CK, Landwehrmeyer GB, et al (2009). Normal and mutant HTT interact to affect clinical severity and progression in Huntington disease. Neurology 73:1280-1285.
6. Bilney B, Morris ME, Perry A (2003). Effectiveness of physiotherapy, occupational therapy and speech pathology for people with Huntington’s disease: a systematic review. Neurorehabil Neural Repair 17:12-24.
7. Bohlen S, Ekwall C, Hellström K, et al (2013). Physical therapy in Huntington’s disease-toward objective assessments? Eur J Neurol 20:389-393.
8. Borowsky B, Warner J, Leavitt BR, et al (2013). 8OHdG is not a biomarker for Huntington disease state or progression. Neurology 80:1934-1941.
9. Busse ME, Khalil H, Quinn L, et al (2008). Physical therapy intervention for people with Huntington disease. Phys Ther 88:820-831.
10. Camiletti-Moirón D, Aparicio VA, Aranda P, et al (2013). Does exercise reduce brain oxidative stress? A systematic review. Scand J Med Sci Sports 23: 202-212.
11. Chen CM, Wu YR, Cheng ML, et al (2007). Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington’s disease patients. Biochem Biophys Res Commun 359:335-340.
12. Ciancarelli I, De Amicis D, Di Massimo C, et al (2012). Oxidative stress in post-acute ischemic stroke patients after intensive neurorehabilitation. Curr Neurovasc Res 9:266-273.
13. Ciancarelli I, Tozzi Ciancarelli MG, Carolei A (2013). Effectiveness of intensive neurorehabilitation in patients with Huntington’s disease. Eur J Phys Rehabil Med 49:189-195.
14. Ciancarelli I, De Amicis D, Di Massimo C, et al (2014). Peripheral biomarkers of oxidative stress and their limited potential in evaluation of clinical features of Huntington’s patients. Biomarkers 19:452-456.
15. Di Massimo C, Scarpelli P, Di Lorenzo N, et al (2006). Impaired plasma nitric oxide availability and extracellular superoxide dismutase activity in healthy humans with advancing age. Life Sci 78:1163-1167.
16. Eidelberg D, Surmeier DJ (2011). Brain networks in Huntington disease. J Clin Invest 121:484-492.
17. Greco A, Minghetti L, Levi G (2000). Isoprostanes, novel markers of oxidative injury, help understanding the pathogene-sis of neurodegenerative diseases. Neurochem Res 25: 1357-1364.
18. Hersch SM, Gevorkian S, Marder K, et al (2006). Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2’dG. Neurology 66:250-252.
19. Johri A, Beal MF (2012). Antioxidants in Huntington’s disease. Biochim Biophys Acta 1822:664-674.
20. Killoran A, Biglan KM (2012). 8-OHdG: its (limited) potential as a biomarker for Huntington’s disease. Biomark Med 6:777-780.
21. Klepac N, Relja M, Klepac R, et al (2007). Oxidative stress parameters in plasma of Huntington’s disease patients, asymptomatic Huntington’s disease gene carriers and healthy subjects: a cross-sectional study. J Neurol 254:1676-1683.
22. Mahoney FI, Barthel DW (1965). Functional evaluation: the Barthel Index. Md State Med J 14:61-65.
23. Milakovic T, Johnson GV (2005). Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J Biol Chem 280:30773-30782.
24. Miller E, Morel A, Saso L, et al (2014). Isoprostanes and neu-roprostanes as biomarkers of oxidative stress in neurodegenerative diseases. Oxid Med Cell Longev 2014: 572491
25. Montoya A, Price BH, Menear M, et al (2006). Brain imaging and cognitive dysfunctions in Huntington’s disease. J Psychiatry Neurosci 31:21-29.
26. Perluigi M, Poon HF, Maragos W, et al (2005). Proteomic analysis of protein expression and oxidative modification in R6/2 transgenic mice. Mol Cell Proteomics 4:1849-1861.
27. Reuben DB, Siu AL (1990). An objective measure of physical function in elderly outpatients. The Physical Performance Test. J Am Geriatr Soc 38:1105-1112.
28. Santamaria A, Pérez-Severiano F, Rodriguez-Martinez E, et al (2001). Comparative analysis of superoxide dismutase activity between acute pharmacological models and a transgenic mouse model of Huntington’s disease. Neurochem Res 26:419-424.
29. Sassone J, Colciago C, Cislaghi G, et al (2009). Huntington’s disease: the current state of research with peripheral tissues. Exp Neurol 219:385-397.
30. Shinozaki K, Oda S, Sadahiro T, et al (2009). S-100B and neuron-specific enolase as predictors of neurological outcome in patients after cardiac arrest and return of spontaneous circulation: a systematic review. Crit Care 13:R121.
31. Siesling S, van Vugt JP, Zwinderman KA, et al (1998). Unified Huntington’s disease rating scale: a follow up. Mov Disord 13:915-919.
32. Shoulson I (1981). Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology 31:1333-1335.
33. Sorolla MA, Reverter-Branchat G, Tamarit J, et al (2008). Proteomic and oxidative stress analysis in human brain samples of Huntington disease. Free Radic Biol Med 45:667-678.
34. Stack EC, Matson WR, Ferrante RJ (2008). Evidence of oxidant damage in Huntington’s disease: translational strategies using antioxidants. Ann NY Acad Sci 1147:79-92.
35. Tinetti ME (1986). Performance-oriented assessment of mobility problems in elderly patients. J Am Geriatr Soc 34:119-126.
36. Trushina E, McMurray CT (2007). Oxidative stress and mito-chondrial dysfunction in neurodegenerative diseases. Neuroscience 145:1233-1248.
37. Tuon T, Valvassori SS, Lopes-Borges J, et al (2012). Physical training exerts neuroprotective effects in the regulation of neurochemical factors in an animal model of Parkinson’s disease. Neuroscience 227:305-312.
38. Tünez I, Sànchez-López F, Agüera E, et al (2011). Important role of oxidative stress biomarkers in Huntington’s disease. J Med Chem 54:5602-5606.
39. Zielonka D, Marinus J, Roos RA, et al (2013). The influence of gender on phenotype and disease progression in patients with Huntington’s disease. Parkinsonism Relat Disord 19:192-197.
40. Zuccato C, Valenza M, Cattaneo E (2010). Molecular mechanisms and potential therapeutical targets in Huntington’s disease. Physiol Rev 90:905-981.